Conavi Medical Corp. (CNVIF)
| Market Cap | 16.42M -32.4% |
| Revenue (ttm) | 595.03K -90.9% |
| Net Income | -14.52M |
| EPS | -0.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.1213 |
| Previous Close | 0.0874 |
| Day's Range | 0.1213 - 0.1213 |
| 52-Week Range | 0.0874 - 0.5550 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 18, 2026 |
About Conavi Medical
Conavi Medical Corp. focuses on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. It offers Novasight Hybrid System, a system that combines intravascular ultrasound and optical coherence tomography to enable simultaneous and co-registered imaging of coronary arteries. Conavi Medical Corp. is based in Toronto, Canada. [Read more]
Financial Performance
In fiscal year 2025, Conavi Medical's revenue was 9.12 million, an increase of 322.12% compared to the previous year's 2.16 million. Losses were -20.52 million, -52.96% less than in 2024.
Financial numbers in CAD Financial StatementsNews
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing,...
Conavi Medical Corp. Announces Closing of $10M Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a co...
Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, July 29, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. ...
Conavi Medical Announces JSCAI Publication Demonstrating the Clinical Utility of Hybrid IVUS OCT Imaging
Publication demonstrates how complementary IVUS and OCT information supports lesion assessment, treatment planning, and stent optimization while helping manage contrast use Publication demonstrates ho...
Conavi Medical Reports Fiscal Second Quarter 2026 Results and Operational Highlights
- Achieves U.S. FDA 510(k) Clearance for Next-Generation Hybrid IVUS-OCT Imaging System- Wins Multiple Industry Awards Recognizing Innovation and Leadership in Intravascular Imaging- Advances U.S. Com...
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
TORONTO, May 11, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and mark...
Conavi Medical Awarded 2026 TAG Innovation Award
Recognition Follows FDA 510(k) Clearance of its Next-Generation Hybrid Intravascular Imaging System Recognition Follows FDA 510(k) Clearance of its Next-Generation Hybrid Intravascular Imaging System
Conavi Medical to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ("Conavi" or the "Company"), a commercial stage medical device company focused on designing, manuf...
Conavi Medical Announces Results from Its Annual General Meeting of Shareholders
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufac...
Conavi Medical Reports Fiscal First Quarter 2026 Results and Operational Highlights
- Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch - Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging
Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging
- New Academic Data Supports Clinical and Commercial Value of Hybrid Imaging Platform- - New Academic Data Supports Clinical and Commercial Value of Hybrid Imaging Platform-
Conavi Medical Corp. Announces Closing of $12M Public Offering
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a co...
Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES A&R FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Co...
Conavi Medical Reports Fiscal Year 2025 Results and Operational Highlights
TORONTO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, ...
Conavi Medical announces agreement with the Province of Ontario as part of the Life Sciences Scale-Up Fund
TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, ...
Conavi Medical to Highlight Novasight Hybrid™ Imaging at TCT 2025
Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technology Company to Participate in Educational Imaging Sessions and Feature Hybrid IVUS/OCT Imaging Technol...
Conavi Medical to Present at the Planet MicroCap Showcase: TORONTO in partnership with MicroCapClub on Wednesday, October 22, 2025
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, ...
Conavi Medical Submits Next Generation Novasight Hybrid Intravascular Imaging System to US FDA for 510(k) Clearance
US FDA 510(k) Submission Follows the Successful Validation Testing with KOLs FDA 510(k) Clearance Anticipated During H1 2026 and Company Preparing for US Commercial Launch following Clearance Coronary...
Conavi Medical Reports Fiscal Q3 2025 Interim Results and Operational Highlights
TORONTO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial-stage medical device company focused on designing, manufac...
Novasight™ Hybrid Imaging System Featured in Published JSCAI Case Report Demonstrating Superior Diagnosis and Precision-Guided Therapy in Complex Coronary Case
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intravascular imaging, is pleased to announce the publication of a compelling case report...
Conavi Medical Applauds New American Journal of Cardiology Study Highlighting Importance of Intracoronary Imaging During PCI
TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intracoronary imaging technologies, is pleased to highlight the recent publication in The...
Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) Investor Webinar with Presentation and Audience Q&A
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi Medical” or the “Company”), is pleased to invite investors and other interested parties to attend t...
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...
Conavi Medical Announces New Grant of Stock Options
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), announced that its board of directors (the “Board”) has approved grants ...
Conavi Medical Reports Fiscal Q2 2025 Interim Results and Operational Highlights
New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition Upsized $20 million financing...